Product Information
BRIMONIDINE 0.2% EYE DROP is a generic product labeled by Bausch & Lomb Incorporated, priced at $0.8530 per ML under NDC 24208041105. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 28, 2003. Its Orange Book therapeutic-equivalence code is AT.
Strength
2 mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208041105
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BRIMONIDINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA076260FDA Approved
5/28/2003
TE Code
AT
On Market Since
5/28/2003
Pharmacological Classes
Price Statistics
The NADAC for BRIMONIDINE 0.2% EYE DROP has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 8.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8530 per ML |
|---|---|
| All-time high | $0.9708 (Nov 13, 2019) |
| All-time low | $0.6907 (May 22, 2024) |
| 52-week high | $0.8530 |
| 52-week low | $0.7695 |
| Median price | $0.8047 |
| Average price | $0.8167 |
| Largest weekly change | +25.0% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 41% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Brimonidine Tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BRIMONIDINE 0.2% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for BRIMONIDINE 0.2% EYE DROP, manufactured by Bausch & Lomb Incorporated, is $0.8530 per ML (NDC 24208041105), effective Sep 30, 2026.
How has the price of BRIMONIDINE 0.2% EYE DROP changed over time?
Over the history we have for it, the NADAC for BRIMONIDINE 0.2% EYE DROP has declined 8.0%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for BRIMONIDINE 0.2% EYE DROP?
Since Nov 28, 2013, the NADAC for BRIMONIDINE 0.2% EYE DROP has ranged from a low of $0.6907 (May 22, 2024) to a high of $0.9708 (Nov 13, 2019), with a median of $0.8047 per ML.
Are there cheaper alternatives to BRIMONIDINE 0.2% EYE DROP?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BRIMONIDINE 0.2% EYE DROP, is $0.5012 per ML — about 41% below BRIMONIDINE 0.2% EYE DROP.
Who manufactures BRIMONIDINE 0.2% EYE DROP?
BRIMONIDINE 0.2% EYE DROP (NDC 24208041105) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.